How Clinical Trial Recruitment Is Becoming More Patient-Centered

In the past, clinical trials were treated as a secondary activity – they were afterthoughts in the treatment of patients. The protocol was the first. The second place was for the site. The one who had to go and do the blood draws and the questionnaires over and over? They were towards the end of the list. This is no longer the case, and it’s changing quickly.

The Old Problem: Recruitment Breaks More Trials, Not Science

Most outside of the industry are surprised to get this number: 80-85% of clinical trials do not meet their initial recruitment objectives, and almost 30% of sites recruit no patients at all. Zero. Not slow. Zero. 

The more one looks into it, the more one finds it to be worse. In a study of 76 global Phase II and III trials conducted at Tufts, the average rate of screen failures increased from 34.7% to 36.3% and the average drop out rate went from 15.3% to 19.1% over the past seven years. Trials are failing not because of the science being incorrect. They’re failing because the persons meant to test that science cannot or will not remain in the study.

Why Patients Used to Come Last

Traditional trial design was site-centric. You built a study around a hospital, a lab, and a research team — then expected patients to rearrange their lives around that geography. For someone with a demanding job, kids, or no car, that’s not a minor inconvenience. It’s a wall.

The data backs this up plainly. Roughly 40–50% of U.S. patients with advanced-stage cancers live at least a one-hour drive from the nearest trial site recruiting for their condition. And when only people who can make that drive end up enrolled, the resulting data skews. Recent analysis of global trials found participants were 76% White, 11% Asian, and just 7% Black, with only 13% identifying as Hispanic or Latino. That’s not a representative slice of the population these drugs are meant to treat. 

The Shift Toward Decentralized, Patient-First Trials

So the industry began to reverse the trend. The sponsors started to ask the question: “How do we bring the trial to the patient? – rather than the traditional question: “How do we get patients to the site?”. The most obvious outcome is decentralized clinical trials, also known as DCTs.

The rollout of Mayo Clinic is a true example of that. The proportion of participants who resided over 120 miles from an academic Mayo location increased from 18.9% in Q1 2024 to 29.6% in Q1 2025. There were also diversity numbers that also moved. The PACT Consortium conducted a review of 69 trials and discovered that Asian representation increased in DCT-enabled trials (20.9%) compared to traditional trials (14.2%), as did the number of American Indian or Alaska Native participants, which nearly quadrupled. But decentralization has not yet done the job — even with it in place, black or African American enrollment remains at only 7.3%. There’s no one solution.

Meeting Patients Where They Are, Literally

Rather than central labs, local ones. Visits to the home instead of the clinic. Non-wage loss tele-health check-ins. These have become essential features of a well-managed study, and not luxuries anymore.

There’s a money reason here, too, not just a compassionate one. Recruitment costs for a patient average about $6,500; replacing a lost patient costs about $19,500. It’s more cost effective to keep someone in, rather than losing them and having to replace them. Sponsors have noticed.

Turning Recruitment Into a Conversation, Not a Cold Call

It is in this way that communication is being rethought. Over the years, patient recruitment involved a scripted voice on the phone calling patients, or a mailed flyer that was not opened. Neither establishes trust, and trust is the only monetary asset of a trial.

Now, dialogue is the foundation. This can be a face-to-face conversation with a person on video chat services, not necessarily a clinic representative; it could be an existing patient. It’s not about marketing or persuasion, but simply communicating. For as long as both parties desire.

Faster Answers, Fewer Drop-Offs

Think about the last time you called a company and sat on hold. Now imagine doing that while also managing a chronic illness. Conversational tools remove that friction, and removing friction is, at its core, what patient-centered design is all about.

Regulation Is Pushing in the Same Direction

This isn’t happening purely out of goodwill. The FDA now requires detailed diversity action plans for many trials, and failing to submit one can lead to costly delays or even rejection of a study. Reputational risk matters too — sponsors that ignore health equity mandates don’t just risk fines, they risk the trust of entire communities they’ll need for future studies. 

Regulators, in effect, forced a question sponsors should have been asking all along: who is actually in this trial, and who got left out?

What This Actually Looks Like Day to Day

Imagine that someone lives in a rural community and joins a heart failure study. A nurse comes to her house to take her vital signs, rather than driving three hours to a site. Her consent forms are in her native tongue. A chatbot provides her with response to a 9PM question about medication timing, instead she has to wait until morning to guess. None of this is science fiction, it is already being implemented in active trials these days.

The toolkit of modern recruitment teams is changing to include multilingual materials, flexible windows of visits, transportation allowances and on-demand digital support. When it’s broken down into little bits, participation doesn’t seem like too much work.

The Road Ahead

Patient-centred recruitment is not a completed endeavour. Some populations continue to have large diversity gaps, and some sponsors do not have the funding to support decentralization in its entirety. The direction of the trials is clear, however, not the other way around – humans are being constructed around the trials.

The industry spent years refining protocols.For years, the industry worked to fine-tune protocols. Now, finally, it’s optimising for people. This transition alone could be more powerful in solving enrollment issues than any one new technology ever could.